Regulatory Updates
🇪🇺 EMA Page 3EMA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
Showing 25–36 of 171 articles
데일리팜 리크루트: Vyloy (zolbetuximab) Reimbursement Progress and Market Implications for Gastric Cancer
Florian Lordick Elected ESMO President 2029–2030: What Pharma Teams Should Watch
From Approval to Access: Europe’s Next Health Imperative for Pharma
EMA, AMA and African Regulators Unite to Accelerate Ebola Clinical Trials
EU Commission Advances Critical Medicines Act: Market Implications
Cancer Therapy OST-HER2 Faces 2026 EMA Call After Survival Data
CHMP May 2026 Output: A New Era in Drug Approvals
WHO/Europe Initiative on Access to Novel Medicines: Market Implications for Pharma
Hayes Receives 2026 ESMO Breast Cancer Award: Key Insights
CHMP Negative Opinion on Acadia's Rett Syndrome Drug: Implications for Investors and Pharma Teams
Pharma People on the Move: Spring 2026 Roundup — Regulatory Updates
Cellectar Biosciences (CLRB) FDA Approvals, PDUFA Dates & Drug Alerts 2026